Search

Displaying results 721 - 730 of 3917 in total
  1. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  2. Drug

    Glutathione

    go.drugbank.com/drugs/DB00143
    ApprovedInvestigationalNutraceutical

    It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

  3. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid [L1496].

    Categories: Anti-Inflammatory Agents, Non-Steroidal, Antiinflammatory and Antirheumatic Products, Non-Steroids
  4. Drug

    Mepivacaine

    go.drugbank.com/drugs/DB00961
    ApprovedInvestigationalVet approved

    A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and t...

    Mixtures: MEPICAIN CON ADRENALINA, MEPICAIN CON ADRENALINA
  5. Drug

    Olanzapine

    go.drugbank.com/drugs/DB00334
    ApprovedInvestigational

    Olanzapine is a thienobenzodiazepine derivative and an atypical or second-generation antipsychotic agent. Its chemical structure contains a thieno[2,3-b][1,5]benzodiazepine core, and has a methyl group attached to the piperazine ring. Th...

    Mixtures: PISAURIT FON
  6. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.

  7. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.

    Categories: Bone Density Conservation Agents
  8. Drug

    Caffeine

    go.drugbank.com/drugs/DB00201
    ApprovedInvestigational

    [L9863] According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. … Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely.

    Mixtures: CON-Z-LIN TABLET
  9. Drug

    Zopiclone

    go.drugbank.com/drugs/DB01198
    ApprovedInvestigational

    Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.

  10. Drug

    Flibanserin

    go.drugbank.com/drugs/DB04908
    ApprovedInvestigational

    Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin … in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.